FDA Approval of Ibrutinib with Rituximab for Waldenström's Macroglobulinemia

Ibrutinib plus Rituximab is now approved by the FDA in Waldenström’s Macroglobulinemia (WM), a rare form of non-Hodgkin’s lymphoma and a sister cancer to CLL. WM is much less common than CLL. With this approval, ibrutinib is now approved for adults with WM in combination with rituximab, representing the first chemotherapy-free combination treatment specifically indicated for this blood cancer.

For more information, click here to see the press release.

While not specifically CLL news, the more options for related blood cancers, the better for all of us as we learn from each other’s experience with the drugs.

About the author

Brad Hedrick

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to Venetoclax tablet Label
September 18, 2018

FDA Approval of Venetoclax in Combination with Rituximab (V+R) for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Who Have Received One Prior Therapy
June 9, 2018

FDA Approves Kymriah (tisagenlecleucel) for DLBCL
May 8, 2018

CLL Copay Assistance is NOW OPEN at the Leukemia & Lymphoma Society
April 17, 2018

FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
April 9, 2018

Imbruvica® (ibrutinib) is Now Available as a Single Tablet
March 23, 2018

FDA Approval of Ibrutinib with Rituximab for Waldenström’s Macroglobulinemia